Pasireotide Completed Phase 2 Trials for Cushing's Syndrome Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00088608A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease